Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | CRB-401: is CAR T-cell therapy the future of multiple myeloma treatment?

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses the exciting preliminary results of the CRB-401 trial (NCT02658929) investigating the efficacy and safety of anti-BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma (MM). Dr Fonesca discusses the trial in terms of response rates and measurable residual disease (MRD) status, and poses that these results are likely to translate well into progression-free and overall survival.